Physician profile
Chelet Bleyl
NPI 1821720046
$2,086.97
in general payments reported to CMS, 2019-2025
25 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $79.15 · 2024: $674 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998 · Education: $89.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.83 |
| Education | $89.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $466.77 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $177.35 | 2024-2025 | Fasenra, Tezspire, Airsupra |
| Novo Nordisk INC | $126.61 | 2025 | Wegovy, Rybelsus, Ozempic |
| Genzyme Corporation | $123.43 | 2024-2025 | |
| Genentech USA, INC. | $123.18 | 2024 | Xolair |
| Regeneron Healthcare Solutions, INC. | $116.07 | 2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $95.58 | 2025 | Neffy |
| Lilly USA, LLC | $87.84 | 2024-2025 | Mounjaro, Ebglyss |
| Organon LLC | $85.59 | 2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $81.27 | 2023-2025 | Takhzyro, Hyqvia, Cuvitru |
| Merck Sharp & Dohme LLC | $80.63 | 2024-2025 | Gardasil 9, Capvaxive, Rotateq |
| Pfizer INC. | $80.62 | 2024-2025 | |
| Csl Behring | $76.22 | 2024-2025 | Hizentra, Andembry, Haegarda |
| Galderma Laboratories, L.P. | $65.93 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $51.35 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $49.26 | 2024-2025 | Ruconest |
| Corium, LLC | $46.32 | 2023-2024 | Azstarys |
| Amgen INC. | $34.79 | 2025 | Tezspire |
| Tersera Therapeutics LLC | $21.88 | 2025 | Quzyttir |
| Biocryst US Sales Co., LLC | $18.03 | 2025 | Orladeyo |
| Kaleo, INC. | $17.58 | 2024 | Auvi-Q |
| Cranial Technologies, INC | $17.04 | 2025 | Doc Band |
| Exact Sciences Corporation | $16.30 | 2025 | Cologuard Collection Kit |
| Blueprint Medicines Corporation | $14.08 | 2024 | Ayvakit |
| C. R. Bard, INC. & Subsidiaries | $13.25 | 2024 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelet Bleyl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.